Exagen Inc (XGN)

Jan 20, 2025

Exagen Gains 28%, Insider Trades Reap Benefit - Yahoo Finance

Jan 20, 2025

Jan 19, 2025

The 26% return this week takes Exagen's (NASDAQ:XGN) shareholders one-year gains to 102% - Simply Wall St

Jan 19, 2025

Jan 17, 2025

Exagen Inc. (XGN) Soars to 52-Week High, Time to Cash Out? - MSN

Jan 17, 2025

Jan 14, 2025

Exagen Inc. Gains Approval for Advanced Lupus and Rheumatoid Arthritis Diagnostic Tests - Lupus Foundation of America

Jan 14, 2025

Jan 14, 2025

Exagen’s (XGN) “Overweight” Rating Reaffirmed at Cantor Fitzgerald - Defense World

Jan 14, 2025

Jan 13, 2025

Cantor Fitzgerald Reaffirms "Overweight" Rating for Exagen (NASDAQ:XGN) - MarketBeat

Jan 13, 2025

Jan 12, 2025

Exagen Inc. Secures Conditional NY State Approval for New - GlobeNewswire

Jan 12, 2025

Jan 12, 2025

Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis - The Bakersfield Californian

Jan 12, 2025

Jan 12, 2025

Exagen Achieves Record $55.8M Revenue, Gets NY Approval for New Lupus & RA Biomarker Tests - StockTitan

Jan 12, 2025

Jan 04, 2025

Exagen (NASDAQ:XGN) Given New $7.00 Price Target at Canaccord Genuity Group - Defense World

Jan 04, 2025

Jan 03, 2025

Exagen (NASDAQ:XGN) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says - MarketBeat

Jan 03, 2025

Dec 29, 2024

Short Interest in Exagen Inc. (NASDAQ:XGN) Grows By 36.5% - Defense World

Dec 29, 2024

Dec 28, 2024

Exagen Inc. (NASDAQ:XGN) Short Interest Up 36.5% in December - MarketBeat

Dec 28, 2024

Dec 25, 2024

Exagen (NASDAQ:XGN) Stock Price Up 1.4%Time to Buy? - MarketBeat

Dec 25, 2024

Dec 25, 2024

Exagen (NASDAQ:XGN) Trading 1.4% Higher – Still a Buy? - Defense World

Dec 25, 2024

Dec 22, 2024

Exagen Inc.'s (NASDAQ:XGN) Share Price Boosted 26% But Its Business Prospects Need A Lift Too - Simply Wall St

Dec 22, 2024

Dec 21, 2024

Learn to Evaluate (XGN) using the Charts - Stock Traders Daily

Dec 21, 2024

Dec 12, 2024

Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD - GlobeNewswire

Dec 12, 2024

Dec 12, 2024

Exagen Hits Major Milestone: 1 Million AVISE Tests Revolutionize Autoimmune Disease Diagnosis - StockTitan

Dec 12, 2024

Dec 11, 2024

Exagen stock soars to 52-week high, hits $4.97 - Investing.com

Dec 11, 2024

Dec 10, 2024

Exagen's SWOT analysis: diagnostic firm's stock poised for growth amid challenges By Investing.com - Investing.com South Africa

Dec 10, 2024

Dec 10, 2024

Exagen's SWOT analysis: diagnostic firm's stock poised for growth amid challenges - Investing.com India

Dec 10, 2024

Dec 04, 2024

Exagen stock soars to 52-week high, hits $4.88 amid robust gains By Investing.com - Investing.com South Africa

Dec 04, 2024

Dec 04, 2024

Exagen stock soars to 52-week high, hits $4.88 amid robust gains - Investing.com Canada

Dec 04, 2024

Dec 02, 2024

Wasatch Advisors LP Sells 272,054 Shares of Exagen Inc. (NASDAQ:XGN) - MarketBeat

Dec 02, 2024

Nov 23, 2024

Exagen stock holds Sector Weight amid mixed 3Q24 results By Investing.com - Investing.com Nigeria

Nov 23, 2024

Nov 21, 2024

Exagen stock soars to 52-week high, hits $3.79 By Investing.com - Investing.com Canada

Nov 21, 2024

Nov 21, 2024

Exagen CEO, President & Director Acquires 7.7% More Stock - Simply Wall St

Nov 21, 2024

Nov 20, 2024

Exagen stock soars to 52-week high, hits $3.79 - Investing.com India

Nov 20, 2024

Nov 20, 2024

Exagen CFO Jeffrey Black acquires $66,448 in common stock - Investing.com India

Nov 20, 2024

Nov 19, 2024

Exagen CFO Jeffrey Black acquires $66,448 in common stock By Investing.com - Investing.com UK

Nov 19, 2024

Nov 19, 2024

Exagen president and CEO John Aballi buys $68,297 in stock By Investing.com - Investing.com Canada

Nov 19, 2024

Nov 18, 2024

Exagen president and CEO John Aballi buys $68,297 in stock - Investing.com

Nov 18, 2024

Nov 18, 2024

What is William Blair’s Forecast for Exagen FY2024 Earnings? - Defense World

Nov 18, 2024

Nov 18, 2024

Research Analysts Issue Forecasts for Exagen FY2024 Earnings - MarketBeat

Nov 18, 2024

Nov 18, 2024

FY2024 EPS Estimates for Exagen Raised by Cantor Fitzgerald - MarketBeat

Nov 18, 2024

Nov 18, 2024

Cantor Fitzgerald Increases Earnings Estimates for Exagen - Defense World

Nov 18, 2024

Nov 15, 2024

Exagen Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Nov 15, 2024

Nov 15, 2024

William Blair Reiterates “Outperform” Rating for Exagen (NASDAQ:XGN) - Defense World

Nov 15, 2024

Nov 14, 2024

Exagen unveils new biomarkers to enhance autoimmune testing - Investing.com

Nov 14, 2024

Nov 14, 2024

Exagen Inc. Completes Validation and Regulatory Submission - GlobeNewswire

Nov 14, 2024

Nov 14, 2024

Exagen Enhances AVISE CTD Platform with 7 New Biomarkers for Autoimmune Disease Detection | XGN Stock News - StockTitan

Nov 14, 2024

Nov 13, 2024

Exagen Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 13, 2024

Nov 13, 2024

Exagen Inc. to Participate in Fourth Quarter Investor Conferences - The Manila Times

Nov 13, 2024

Nov 13, 2024

Exagen CEO to Present at Three Major Healthcare Investor Conferences | XGN Stock News - StockTitan

Nov 13, 2024

Nov 13, 2024

Exagen (NASDAQ:XGN) Receives Outperform Rating from William Blair - MarketBeat

Nov 13, 2024

Nov 13, 2024

Exagen Inc. (NASDAQ:XGN) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 13, 2024